April 2020 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender, dated 1 November 2019.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by:
- For new listings, by 4pm on 12 May 2020 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Ondansetron |
Tab disp 4 mg; |
$0.95 |
$0.76 |
Ondansetron ODT-DRLA |
1 July 2020 |
1 October 2020 |
|
Ondansetron |
Tab disp 8 mg; |
$1.43 |
$1.13 |
Ondansetron ODT-DRLA |
1 July 2020 |
1 October 2020 |
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Sole Subsidised Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Bisoprolol fumarate1 |
Tab 2.5 mg; |
$3.53 |
$1.84 |
Bisoprolol Mylan |
1 September 2020 |
1 February 2021 |
Bosvate (Douglas) |
|
Bisoprolol fumarate1 |
Tab 5 mg; |
$5.15 |
$2.55 |
Bisoprolol Mylan |
1 September 2020 |
1 February 2021 |
Bosvate (Douglas) |
|
Bisoprolol fumarate1 |
Tab 10 mg; |
$9.40 |
$3.62 |
Bisoprolol Mylan |
1 September 2020 |
1 February 2021 |
Bosvate (Douglas) |
|
Darunavir2 |
Tab 400 mg, |
$355.00 |
$132.00 |
Darunavir Mylan |
1 November 2020 |
1 April 2021 |
Prezista (Janssen-Cilag) |
|
Darunavir2 |
Tab 600 mg, |
$476.00 |
$196.55 |
Darunavir Mylan |
1 November 2020 |
1 April 2021 |
Prezista (Janssen-Cilag) |
|
Metronidazole |
Tab 200 mg; |
$36.35 |
$33.15 |
Metrogyl (Mylan) |
1 September 2020 |
1 December 2020 |
Trichozole (Mylan) |
|
Metronidazole |
Tab 400 mg; |
$5.55 |
$5.23 |
Metrogyl (Mylan) |
1 September 2020 |
1 December 2020 |
Trichozole (Mylan) |
|
Tobramycin |
Solution for inhilation 60 mg per ml, 5 ml; |
$2,200.00 |
$395.00 |
Tobramycin BNM |
1 September 2020 |
1 February 2021 |
TOBI |
|
1 Brand switch fee of $4.50 is payable for this product from 1 February 2021 to 30 April 2021 2 Brand switch fee of $4.50 is payable for this product from 1 April 2021 to 30 June 2021 |
|||||||
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Clarithromycin |
Inj 500 mg vial; 1 vial pack |
$12.04 |
$9.87 |
Martindale (Max health) |
1% |
1 September 2020 |
1 December 2020 |
|
Ondansetron |
Tab disp 4 mg; |
$0.95 |
$0.76 |
Ondansetron ODT-DRLA |
1% |
1 July 2020 |
1 October 2020 |
|
Ondansetron |
Tab disp 8 mg; |
$1.43 |
$1.13 |
Ondansetron ODT-DRLA |
1% |
1 July 2020 |
1 October 2020 |
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand (Supplier) |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Bisoprolol fumarate |
Tab 2.5 mg; |
$3.53 |
$1.84 |
Bisoprolol Mylan |
1% |
1 September 2020 |
1 February 2021 |
Bosvate (Douglas) |
|
Bisoprolol fumarate |
Tab 5 mg; |
$5.15 |
$2.55 |
Bisoprolol Mylan |
1% |
1 September 2020 |
1 February 2021 |
Bosvate (Douglas) |
|
Bisoprolol fumarate |
Tab 10 mg; |
$9.40 |
$3.62 |
Bisoprolol Mylan |
1% |
1 September 2020 |
1 February 2021 |
Bosvate (Douglas) |
|
Ceftazidime |
Inj 1 g vial; |
$34.00 |
$2.69 (per 1) |
Ceftazidime-AFT |
1% |
1 July 2020 |
1 December 2020 |
Ceftazidime Mylan |
|
Darunavir |
Tab 400 mg, |
$355.00 |
$132.00 |
Darunavir Mylan |
1% |
1 November 2020 |
1 April 2021 |
Prezista (Janssen-Cilag) |
|
Darunavir |
Tab 600 mg, |
$476.00 |
$196.55 |
Darunavir Mylan |
1% |
1 November 2020 |
1 April 2021 |
Prezista (Janssen-Cilag) |
|
Meropenem |
Inj 500 mg vial: |
$4.00 |
$33.92 |
Meropenem-AFT |
1% |
1 November 2020 |
1 April 2021 |
Meropenem Ranbaxy |
|
Meropenem |
Inj 1 g vial: |
$8.00 |
$45.04 |
Meropenem-AFT |
1% |
1 November 2020 |
1 April 2021 |
Meropenem Ranbaxy |
|
Metronidazole |
Tab 200 mg; |
$36.35 |
$33.15 |
Metrogyl (Mylan) |
1% |
1 September 2020 |
1 December 2020 |
Trichozole (Mylan) |
|
Metronidazole |
Tab 400 mg; |
$5.55 |
$5.23 |
Metrogyl (Mylan) |
1% |
1 September 2020 |
1 December 2020 |
Trichozole (Mylan) |
|
Suxamethonium chloride |
Inj 50 mg per ml, 2 ml amouple; |
$78.00 |
$23.40 |
Martindale |
1% |
1 September 2020 |
1 February 2021 |
AstraZeneca |
|
Tobramycin |
Solution for inhalation 60 mg per ml, 5 ml; |
$2,200.00 |
$395.00 |
Tobramycin BNM |
1% |
1 September 2020 |
1 February 2021 |
TOBI |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
2019/20 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Ajmaline |
Inj 50 mg per 10 ml |
|
Albendazole |
Tab |
|
Amisulpride |
Oral liq |
|
Aztreonam |
Inj 1 g |
|
Benzoyl peroxide |
Soln/Gel/Cream/Lotion 5% |
|
Benzylpenicillin Sodium [Penicillin G] |
Inj 3 g |
|
Budesonide |
Nebuliser soln, 500 mcg per ml, 2 ml |
|
Budesonide |
Nebuliser soln 250 mcg per ml, 2 ml ampoule |
|
Buserelin Acetate |
Inj 1 mg per ml, 5.5 ml |
|
Carmellose sodium |
Paste |
|
Carmellose sodium |
Powder |
|
Carmellose sodium |
Eye drops 0.5% |
|
Chloramphenicol |
Inj 1 g |
|
Chlorpheniramine Maleate |
Oral liq 2 mg per 5 ml |
|
Chlorpheniramine Maleate |
Inj 10 mg per ml |
|
Choline salicylate |
Oral gel |
|
Diazoxide |
Cap 100 mg |
|
Diazoxide |
Cap 25 mg |
|
Diazoxide |
Oral liq 50 mg per ml |
|
Diazoxide |
Inj 15 mg per ml, 20 ml |
|
Diclofenac sodium |
Suppos 12.5 mg |
|
Diclofenac sodium |
Suppos 25 mg |
|
Diclofenac sodium |
Suppos 50 mg |
|
Diclofenac sodium |
Suppos 100 mg |
|
Dorzolamide hydrochloride |
Eye drops 2% |
|
Epoprostenol (current access) |
Inj 1.5 mg vial |
|
Epoprostenol (current access) |
Inj 500 mcg vial |
|
Epoprostenol (widened access) |
Inj 1.5 mg vial |
|
Epoprostenol (widened access) |
Inj 500 mcg vial |
|
Etoposide |
Inj 20 mg per ml, 5 ml |
|
Etoposide phosphate |
Inj 100 mg (of etoposide base) |
|
Famotidine |
Tab 20 mg |
|
Famotidine |
Tab 40 mg |
|
Famotidine |
Inj |
|
Gentamicin Sulphate |
Inj 40 mg per ml, 2 ml |
|
Gentamicin Sulphate |
Inj 10 mg per ml |
|
Hydrocortisone butyrate |
Cream/lipocream 0.1% (pack size 30 g or less) |
|
Hydrogen peroxide |
Soln 3% (10 vol) |
|
Hydrogen Peroxide |
Crm 1% |
|
Hypromellose |
Eye drops 0.5% |
|
Hypromellose |
Eye drops 0.3% |
|
Insulin syringes, disposable with attached needle |
Syringe 0.3 ml with 29 g x 4 mm needle |
|
Insulin syringes, disposable with attached needle |
Syringe 0.5 ml with 29 g x 4 mm needle |
|
Insulin syringes, disposable with attached needle |
Syringe 1 ml with 29 g x 4 mm needle |
|
Levofloxacin |
Tab 500 mg |
|
Magnesium |
Cap/Tab (150 mg elemental) |
|
Mebendazole |
Tab 100 mg |
|
Mitomycin C |
Inj 10 mg - 20 mg |
|
Mitomycin C |
Inj 2 mg - 5 mg |
|
Morphine |
Inj 10 mg per ml, 100 mg cassette |
|
Mucilaginous Laxatives |
Dry |
|
Nifedipine |
Tab long-acting 10 mg |
|
Nifedipine |
Tab long-acting 20 mg |
|
Nifedipine |
Tab long-acting 30 mg |
|
Nifedipine |
Tab long-acting 60 mg |
|
Oxybutynin |
Tab 5 mg |
|
Oxybutynin |
Oral liq 1 mg per ml |
|
Pamidronate disodium |
Inj 3 mg per ml, 10 ml |
|
Pamidronate disodium |
Inj 6 mg per ml, 10 ml |
|
Pamidronate disodium |
Inj 9 mg per ml, 10 ml |
|
Phentolamine Mesylate |
Inj 10 mg per ml, 1 ml |
|
Phentolamine mesylate |
Inj 5 mg per ml, 1 ml |
|
Pivmecillinam |
Tab 200 mg |
|
Podophyllotoxin |
Soln 0.5% |
|
Poractant Alfa |
Soln 120 mg per 1.5 ml vial |
|
Prazosin Hydrochloride |
Tab 1 mg |
|
Prazosin Hydrochloride |
Tab 2 mg |
|
Prazosin Hydrochloride |
Tab 5 mg |
|
Primaquine phosphate |
Tab 7.5 - 15 mg |
|
Propafenone hydrochloride |
Tab 150 mg |
|
Ranitidine hydrochloride |
Oral liq 150 mg per 10 ml |
|
Ranitidine hydrochloride |
Tab 150 mg |
|
Ranitidine hydrochloride |
Tab 300 mg |
|
Ranitidine hydrochloride |
Inj |
|
Risperidone |
Inj 25 mg vial |
|
Risperidone |
Inj 37.5 mg vial |
|
Risperidone |
Inj 50 mg vial |
|
Ropivacaine hydrochloride |
Inj 1 mg per ml, 100 ml bag |
|
Ropivacaine hydrochloride |
Inj 1 mg per ml, 200 ml bag |
|
Ropivacaine hydrochloride with fentanyl |
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag |
|
Ropivacaine hydrochloride with fentanyl |
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag |
|
Ropivacaine hydrochloride with fentanyl |
Inj 1 mg with fentanyl 2 mcg per ml, 100 ml bag |
|
Ropivacaine hydrochloride with fentanyl |
Inj 1 mg with fentanyl 2 mcg per ml, 200 ml bag |
|
Salicylic Acid |
Powder |
|
Sodium fusidate [fusidic acid] |
Eye drops 1% |
|
Tetracycline |
Tab 250 mg |
|
Tetracycline |
Cap 500 mg |
|
Thiamine Hydrochloride |
Tab 100 mg |
|
Thiamine Hydrochloride |
Inj 100 mg per ml, 2 ml |
|
Thiamine hydrochloride |
Inj 100 mg per ml, 1 ml |
|
Tolterodone tartrate |
Tab 1 mg |
|
Tolterodone tartrate |
Tab 2 mg |
|
Triclosan |
Soln 1% |
|
Valganciclovir |
Oral liq |
|
Verapamil hydrochloride |
Inj 2.5 mg per ml, 2 ml |
|
Verapamil hydrochloride |
Tab 40 mg |
|
Verapamil hydrochloride |
Tab 80 mg |
|
Yellow jacket wasp venom |
Inj with diluent for extract |
|
Yellow jacket wasp venom |
Treatment kit |
2018/19 Invitation to Tender
|
Chemical name |
Line item |
|
Octreotide (somatostatin analogue) |
LAR 10 mg pre-filled syringe |
|
Octreotide (somatostatin analogue) |
LAR 20 mg pre-filled syringe |
|
Octreotide (somatostatin analogue) |
LAR 30 mg pre-filled syringe |
For products included in the 2017/18 and 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.
##Date##
2020-04-30
##Leader##
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender, dated 1 November 2019.
##RelatedInfo##
##Author##
Kim Ellis